IMF Videos Search Content For Healthcare Professional (122) Healthcare Provider (122) Care Partner (75) Patient (74) Series - Any - ASCO/EHA (49) ASH (60) Ask Dr. Durie (16) Black Swan Research Initiative (5) Community Workshops (4) Emerging Therapies (6) Facebook Live (10) Health Equity (2) IMWG (3) Inspirational (3) Living Well with Myeloma (4) Myeloma in a Minute (1) Myeloma Made Simple (3) Patient & Family Webinar (4) Q&A (7) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (65) High-Risk Myeloma (42) High-risk Smoldering Myeloma (34) Late Relapse (4–6 Lines of Therapy) (81) MGUS (35) Newly Diagnosed (Pre-Treatment or First Treatment) (64) Smoldering Myeloma (50) Types of Therapy Immunomodulatory drugs (IMiDs) (58) Immunotherapies (CAR T; BiTE, etc.) (93) Monoclonal antibodies (48) Proteasome inhibitors (43) Stem cell transplant (40) Steroids (41) Supportive Care (36) Year Published 2026 (16) 2025 (38) 2024 (58) 2023 (39) 2022 (10) 2021 (7) 2020 (1) 2019 (9) 2018 (2) 2017 (1) 2016 (3) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (15) Dr. María-Victoria Mateos (6) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Dr. Saad Usmani (3) Dr. Sigurður Kristinsson (3) Dr. Shaji Kumar (2) Dr. Urvi A. Shah (2) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance How Mentorship is Reducing Health Disparities in Multiple Myeloma with Special Guest Dr. Saad Usmani October 24, 2024 Health Equity 5 Multiple Myeloma Research Highlights: 2024 International Myeloma Society Meeting | For Patients October 17, 2024 Emerging Therapies Urgent Need for Diversity and Inclusion in Myeloma Clinical Trials | The Maui Declaration September 26, 2024 Health Equity What is Immunotherapy for Multiple Myeloma? Understanding Its Role in Treatment September 12, 2024 Trending Searches in Myeloma Key Multiple Myeloma Abstracts Presented at 2024 ASCO and EHA Meeting August 1, 2024 ASCO/EHA Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32 July 31, 2024 ASCO/EHA MagnetisMM-30, a Phase 1b Study of ELRA and IBER Combination in Relapsed Refractory Multiple Myeloma July 15, 2024 ASCO/EHA DREAMM-7: Belamaf+BVd vs DVd in RRMM, subgroup analyses of phase 3 trial comparing regimens after relapse July 12, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 28, 2024 ASCO/EHA Phase I Study: Dual Targeting BCMA & CD19 FASTCAR-T for High-Risk Multiple Myeloma June 27, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 24, 2024 ASCO/EHA Class comparison of BCMA-directed therapies in relapsed multiple myeloma June 24, 2024 ASCO/EHA Load More
